Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 0409-1700

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 0409-1700). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Bortezomib 01)

Chemical structure of Bortezomib showing its molecular components including boronic acid and aromatic rings, consistent with its chemical properties as an active pharmaceutical ingredient.*

FDA Label Image

Figure 1 (Bortezomib 02)

A Kaplan-Meier survival curve chart showing the percentage of patients over time (in months) for two groups: B-MP and MP. The vertical axis represents the percentage of patients, and the horizontal axis represents time in months up to 26 months. Numbers of patients at risk are listed below the time axis for both groups. The chart includes a p-value from a log-rank test indicating statistical comparison between the groups.*

FDA Label Image

Figure 2 (Bortezomib 03)

A line graph depicting the percentage of patients over time (in months), comparing two groups labeled B-MP and MP. The graph shows the decline in patient percentage over a period of up to 78 months, with the B-MP group maintaining a higher percentage of patients than the MP group. Patient counts at risk are indicated below the x-axis for various time points, along with a note of statistical significance (p < 0.05) from a log-rank test.*

FDA Label Image

Figure 3 (Bortezomib 04)

A survival curve graph comparing the proportion of patients over time (days) for Bortezomib and Dexamethasone treatments. The graph includes patient counts at specific time points and a p-value from a log-rank test indicating statistical comparison of the two treatments.*

FDA Label Image

Figure 4 (Bortezomib 05)

A Kaplan-Meier survival curve comparing the proportion of patients over time (days) between two treatments: Bortezomib and Dexamethasone. The graph shows patient counts at specific time points and includes a p-value indicating statistical significance from a log-rank test.*

FDA Label Image

Figure 5 (Bortezomib 06)

A Kaplan-Meier survival curve chart showing the percentage of patients over time in months for two treatment groups, VcR-CAP and R-CHOP. The chart includes a log-rank test p-value less than 0.001 and a table of subjects at risk at various time points for both groups.*

FDA Label Image

Figure 6 (Bortezomib 07)

A survival curve chart showing the percentage of subjects alive over months from randomization for two treatment groups, VcR-CAP and R-CHOP. The solid line represents VcR-CAP and the dashed line represents R-CHOP. The chart includes a hazard ratio with 95% confidence interval (0.66 [0.51, 0.85]) and a table of subjects at risk at different time points.*

FDA Label Image

Logo (Bortezomib 08)

FDA Label Image

Principal Display Panel (3.5 mg Vial Label)

Bortezomib for Injection 3.5 mg/vial label showing brand name and strength prominently. The label specifies the product as a single dose vial for intravenous or subcutaneous use. Manufacturer Hospira, Inc. and location details in the USA and India are included. Contains barcode and instructions for storage at 20° to 25°C with protection from light. Notes that the vial contains lyophilized bortezomib with mannitol and that unused portions should be discarded.*

FDA Label Image

Principal Display Panel (3.5 mg Vial Carton)

The packaging label for Bortezomib for Injection 3.5 mg/vial, a lyophilized powder for solution. It is a single-dose vial for intravenous or subcutaneous use. The label includes reconstitution instructions, dosage concentration details, storage guidance, and manufacturer information. The product is labeled under Hospira, Inc., and indicates it is made in India. The label also features a barcode and branding.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.